Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

ARQ 197 in Subjects With Metastatic Solid Tumors

Study:

A Phase 1 Dose Escalation Study of ARQ 197 in Adult Patients With Metastatic Solid Tumors

Rationale:

n/a

Purpose:

To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Cancer
Tumor		 Drug: ARQ 197 Phase 1

Verified by ArQule August, 2009

Sponsored by: ArQule
Information provided by: ArQule
ClinicalTrials.gov identifier: NCT00302172

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Control: Uncontrolled, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

The Cleveland Clinic
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.